hackint0sh/New-Dataset huggingface dataset:
Participants will be asked to take images of barriers during physical activity, facilitators during physical activity, feelings during physical activity and types of physical activity they take part in for 8 days after their final pulmonary rehabilitation class. Participants will then take part in a semi-structured interview about the images their have taken while doing physical activity. conditions: Chronic Obstructive Pulmonary Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ESTIMATED measure: Phase 1 - Semi-structured Interviews measure: Phase 2 - Differences between time spent in PA intensity expressed in absolute and relative intensity. measure: Phase 1 - Medical Research Council (MRC) Dyspnoea Scale measure: Phase 1 - COPD Assessment Test (CAT) measure: Phase 1 - Chronic Respiratory Questionnaire (CRQ-SR) measure: Phase 1 - Photovoice and photo-elicitation measure: Phase 2 - Medical Research Council (MRC) Dyspnoea Scale measure: Phase 2 - COPD Assessment Test (CAT) measure: Phase 2 - Chronic Respiratory Questionnaire (CRQ-SR) measure: Phase 2 - Gait Analysis measure: Phase 2 - Exercise Capacity (ISWT) measure: Phase 2 - Exercise Capacity (ESWT) measure: Daily PROactive Physical Activity instrument in COPD (D-PPAC) measure: Phase 2 - Photovoice and photo-elicitation sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NIHR Leicester Biomedical Research Centre - Respiratory status: RECRUITING city: Leicester state: Leicestershire zip: LE67 2DU country: United Kingdom name: Phoebe H Lloyd-Evans role: CONTACT phone: +441162502758 email: phile1@leicester.ac.uk name: Mark W Orme role: CONTACT email: mwo4@leicester.ac.uk name: Mark W Orme role: PRINCIPAL_INVESTIGATOR lat: 52.6386 lon: -1.13169 hasResults: False
nctId: NCT06330610 id: 2021/0378/HP briefTitle: Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Ventilation in Intensive Care Unit acronym: ENNUT-CI overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-06-01 date: 2027-08-01 date: 2024-03-26 date: 2024-03-26 name: University Hospital, Rouen class: OTHER briefSummary: This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU. conditions: Intermittent Fasting conditions: Septic Shock conditions: Organ Failure, Multiple studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 174 type: ESTIMATED name: Intermittent enteral nutrition measure: Evolution of variation of the SOFA (Sepsis-related organ failure assessment) score. measure: evaluation of caloric intake measure: evaluation of protein intake measure: Measurement of nutritionnal status measure: Evaluation of the digestive symptoms measure: Evaluation of the nosocomial infections measure: Evaluation of the metabolic response measure: Evaluation of the duration of hospitalisation measure: Evaluation of the intensive care neuromuscular weakness measure: Evaluation of death measure: Evaluation of quality of life sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330597 id: 21-5196 briefTitle: NIVIA-Hemodynamics overallStatus: RECRUITING date: 2021-07-17 date: 2024-08-31 date: 2024-12-31 date: 2024-03-26 date: 2024-03-26 name: University Health Network, Toronto class: OTHER briefSummary: This is an investigator-initiated, single-center, single-arm prospective study to compare non-invasive hemodynamic assessment using transthoracic echocardiography (TTE) and lung ultrasound (LUS) and hemodynamic assessment using PAC. Patients who have been hemodynamically assessed using PAC will be invited to participate. Each patient will undergo TTE and LUS immediately after first invasive assessment, and again daily after PAC assessments. conditions: Cardiogenic Shock conditions: Heart Failure conditions: Shock conditions: Hemodynamic Instability studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Echocardiography and lung ultrasound measure: Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP. measure: Correlation between cardiac output measured by echocardiography (using LVOT diameter and VTI) and by PAC (using thermodilution) measure: Correlation between right atrial pressure assessed by echocardiography (using IVC diameter and respiratory variation) and by PAC measure: Correlation between pulmonary pressure assessed by echocardiography (using TR max velocity and estimated RAP) and by PAC measure: Correlation between pulmonary pressure assessed by echocardiography (using PAT) and by PAC measure: Correlation between PVR assessed by echocardiography (using PAT) and by PAC measure: Correlation between right ventricular function assessed by echocardiography (using TAPSE and S') and by PAC (using PAPI and RVSWI) measure: Correlation between E/e' ratio and PCWP vs. correlation between lung ultrasound score and PCWP. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Health Network status: RECRUITING city: Toronto state: Ontario zip: M5G 2N2 country: Canada name: Yishay Szekely, MD role: CONTACT phone: 4163404800 email: Yishay.szekely@uhn.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06330584 id: AIM Care Study briefTitle: Administration of Intranasal Midazolam for Anxiety in Palliative Care acronym: AIM Care overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-10-31 date: 2024-10-31 date: 2024-03-26 date: 2024-03-26 name: Insel Gruppe AG, University Hospital Bern class: OTHER name: University Hospital, Basel, Switzerland name: University Hospital, Zürich name: Stadtspital Zürich briefSummary: The goal of this double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study (three study arms) is to describe effects and safety of different doses of intranasal midazolam to treat acute anxiety in palliative care patients, while providing pharmacokinetic and pharmacodynamic data. conditions: Anxiety conditions: Acute Anxiety studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double-blind, randomized, placebo-controlled parallel-group multicenter exploratory pilot study with 3 study arms primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: All study personnel except the personnel at the facility preparing the investigational medicinal product (IMP) (Hospital Pharmacy, University Hospital Basel), and all patients will be blinded to the assigned treatment. Allocation will be concealed using sequentially coded drug packs (using consecutive patient identification numbers from 1 to at least 30) containing the IMP that are otherwise identical. Each drug pack will contain two nasal sprays of identical appearance. Patients and all trial personnel involved in recruitment and care of patients, trial assessment, monitoring, and analyses will be blinded to the assigned trial arm. Blinding will be upheld until the last patient (at least 30 patients, i.e., at least 10 per study arm) has completed the pilot study and data entry into the trial database has been completed.
To safeguard blinding, placebo formulation will be produced with the same pH as the active study drug formulations to mimic nasal irritation induced by verum sprays. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Placebo Nasal Spray 0 mg/spray name: Midazolam Nasal Spray 0.45 mg/spray name: Midazolam Nasal Spray 0.9 mg/spray measure: Change from baseline in anxiety levels, measured by Visual Analogue Scale (VAS) measure: Change from baseline in anxiety levels, measured by Numerical Rating Scale (NRS) measure: Sedation measure: Oxygen saturation SaO2 (percent %) measure: Heart rate (bpm) measure: Cortisol levels in oral fluid measure: Time to first requested additional dose measure: Cumulative number of doses over 24 hours measure: Number of patients with adverse drug events (ADEs) measure: Peak plasma concentration (Cmax) measure: Time to reach the peak plasma concentration (Tmax) measure: Elimination half-life (t1/2) measure: Area under the curve (AUC0-Τ, AUC0-∞) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Inselspital, Universitätsspital Bern city: Bern zip: 3010 country: Switzerland name: Manuel Haschke, MD role: CONTACT phone: +41 (0)31 632 67 93 email: manuel.haschke@insel.ch name: Manuel Haschke role: PRINCIPAL_INVESTIGATOR lat: 46.94809 lon: 7.44744 facility: Universitäres Zentrum für Palliative Care (UZP) city: Bern country: Switzerland name: Steffen Eychmüller, MD role: CONTACT phone: +41 (0)31 632 51 07 email: steffen.eychmueller@insel.ch lat: 46.94809 lon: 7.44744 facility: Zentrum für Palliative Care, Stadtspital Zürich city: Zürich zip: 8037 country: Switzerland name: Andreas Major, MD role: CONTACT phone: +41 (0)44 417 29 26 email: andreas.major@stadtspital.ch lat: 47.36667 lon: 8.54999 facility: Kompetenzzentrum Palliative Care, Universitätsspital Zürich city: Zürich zip: 8091 country: Switzerland name: Caroline Hertler, MD role: CONTACT phone: +41 (0)44 255 29 34 email: caroline.hertler@usz.ch lat: 47.36667 lon: 8.54999 hasResults: False
nctId: NCT06330571 id: Aligners in distalization briefTitle: The Efficiency of Clear Aligners in Maxillary Molar Distalization: A Randomized Clinical Trial. acronym: Aligner overallStatus: RECRUITING date: 2024-04-27 date: 2025-01-15 date: 2025-07-15 date: 2024-03-26 date: 2024-03-26 name: Ain Shams University class: OTHER briefSummary: The aim of this study is to evaluate the accuracy of clear aligners on the amount of the maxillary molar distalization. conditions: Orthodontic Aligners studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 10 type: ESTIMATED name: Molar distalization by aligners with attachment measure: Efficiency of aligners in molar distalization measure: Amount of anchorage loss measure: Amount of molar tipping sex: ALL minimumAge: 15 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Ainshams university status: RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06330558 id: pheos briefTitle: Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma. overallStatus: COMPLETED date: 2016-09-01 date: 2023-09-01 date: 2023-09-01 date: 2024-03-26 date: 2024-03-28 name: Zagazig University class: OTHER_GOV briefSummary: Context: Adrenalectomy for pheochromocytoma (PHEO) poses difficulties due to the elevated chance of conversion. The objective of this study was to conduct a comparative analysis of the occurrence and determinants of conversion in left-sided abdominal laparoscopic adrenalectomy (LLA) and right-sided abdominal laparoscopic adrenalectomy (RLA).
Methods: A retrospective analysis was conducted to include a total of 271 patients diagnosed with PHEO. These patients were separated into two groups: LRA (N=121) and LLA (N=150). The study period spanned from September 2016 to September 2023. conditions: Adrenal Tumor studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 271 type: ACTUAL name: laparoscopic right adrenalectomy measure: conversion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330545 id: STUDY02002161 briefTitle: Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-04 date: 2032-04 date: 2024-03-26 date: 2024-03-26 name: Dartmouth-Hitchcock Medical Center class: OTHER briefSummary: The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are:
* Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy conditions: Dupuytren Contracture studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a prospective phase II trial where patients diagnosed with late/advanced stage Dupuytren's Contracture (DC) who undergo successful CCH injection and release will receive a standardized regimen of radiotherapy (RT). The study will be powered to assess the outcome in patients undergoing the combination of successful release followed by RT. Patients will be monitored for acute and late toxicities while we evaluate disease recurrence defined as a \> 20 degree worsening of contracture in the presence of a palpable cord, or the need for medical/surgical intervention to correct the new or worsening contracture. primaryPurpose: PREVENTION masking: NONE count: 95 type: ESTIMATED name: Radiation therapy measure: Recurrence of Dupuytren's Contracture measure: Radiation Toxicity measure: Patient Reported Outcomes after Radiation Treatment (RT) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330532 id: 4-2023-1526 briefTitle: Impact of Preoperative Frailty and Cognitive Impairment on Postoperative Outcomes in Elderly Cardiac Surgery Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2025-02-28 date: 2025-02-28 date: 2024-03-26 date: 2024-03-26 name: Yonsei University class: OTHER briefSummary: This is a retrospective study of patients aged 65 years and older who underwent cardiac and aortic surgery between March 5, 2021 and October 12, 2022 in the operating room of Severance Cardiovascular Hospital to determine the impact of physical frailty as well as nutritional status, emotional dysregulation, and cognitive dysfunction on postoperative outcomes. Physical frailty will be determined by the Clinical Frailty Scale, handgrip strength, and nutritional status, cognitive dysfunction will be determined by the K-MMSE and K-MoCA administered at the preoperative interview, and emotional dysregulation will be determined using the SGDS-K. These were measured during the pre-anesthesia evaluation and only results from patients who agreed to be tested will be used. Nutritional status will be analyzed based on blood test values measured within one month of surgery. conditions: Cardiovascular Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 450 type: ESTIMATED measure: postoperative all cause mortality measure: major composite morbidity measure: the number of days not in hospital measure: The number of participants who die sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Yonsei University Health system, Severance Hospital city: Seoul zip: 03722 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06330519 id: Ainshams University Dentistry briefTitle: Impact of Different Techniques on The Efficacy of Anaesthesia in Mandibular Molars With Acute Irreversible Pulpitis overallStatus: COMPLETED date: 2023-09-25 date: 2024-02-21 date: 2024-02-21 date: 2024-03-26 date: 2024-03-26 name: Ain Shams University class: OTHER briefSummary: The goal of this clinical trial is to assess the effect of
Researchers will compare cryotherapy to see if it increases the success rate of inferior alveolar nerve block. conditions: Pulpitis - Irreversible studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 72 type: ACTUAL name: Dexamethasone sodium phosphate injection name: 1,1,1,2 tetrafluoroethane name: intraoral soft tissue cryotherapy measure: The effect of intraligamentary dexamethazone injection on the success rate of inferior alveolar nerve block sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Ain Shams University city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06330506 id: 123456123456 briefTitle: The Effect of Pressure Ulcer Care Package on the Risk of Pressure Ulcer Development overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-08-10 date: 2024-09-10 date: 2024-03-26 date: 2024-03-26 name: Cukurova University class: OTHER briefSummary: This study aimed to determine the effect of pressure ulcer care package use on the risk of pressure ulcer development due to surgery in patients undergoing orthopedic surgery. It was planned as a randomized controlled study. The population of the study will consist of patients who underwent surgery in the Orthopaedics and Traumatology Clinic of Doğubayazıt Dr.Yaşar Eryılmaz State Hospital Hospital Hospital of Ağrı Provincial Health Directorate. The sample of the study will consist of patients who volunteered to participate in the study that meets the inclusion criteria. To obtain research data, the Personal Information Form developed by the researcher in line with the literature, 3S Operating Theatre Pressure Wound Risk Assessment Scale, Pressure Wound Regions and Stages Monitoring Form prepared according to NPUAP (2016) Pressure Wound Staging System Form will be used. Statistical analysis of the data obtained from the study will be performed using the SPSS 25 (Statistical Package of Social Science) package program. conditions: Pressure Ulcer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 102 type: ESTIMATED name: Pressure ulcer prevention pack measure: Evaluation of pressure ulcer formation sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330493 id: AcoArt BTK Global Trial briefTitle: AcoArt Litos PCB Below-the-knee Global Trial overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-10 date: 2030-12 date: 2024-03-26 date: 2024-04-29 name: Acotec Scientific Co., Ltd class: INDUSTRY briefSummary: The objective of this study is to assess whether efficacy of the AcoArt Litos PCB is superior and whether safety of AcoArt Litos PCB is noninferior to the control device (FDA cleared PTA Balloon Catheter) regarding treatment of obstructions in the infrapopliteal arteries (located distal to the P3 segment of the popliteal artery and extending to the tibiotalar joint) in patients presenting with chronic limb-threatening ischemia (CLTI)(Rutherford 4-5) conditions: Chronic Limb-Threatening Ischemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 288 type: ESTIMATED name: PCB name: PTA measure: Primary Efficacy Endpoint: Composite of freedom from major amputation and primary patency measure: Primary Safety Endpoint: Composite of MALE and POD (Major Adverse Limb Event + Peri-Operative Death) measure: Composite of Limb Salvage and Primary Patency measure: Patency rate measure: Freedom from CD-TLR measure: Re-occlusion rate of target lesion measure: Rate of Major adverse events(MAE) measure: Rate of target limb major amputation measure: Rate of all-cause death measure: Amputation free survival rate measure: Change in ankle-brachial index(ABI) measure: Change in toe-brachial index(TBI) measure: Change in Rutherford category measure: Change in EQ-5D measure: Change in VascuQol measure: Primary sustained clinical improvement measure: Secondary sustained clinical improvement measure: Wound healing measure: Rate of Device Success measure: Rate of Technical Success measure: Rate of Procedure Success sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06330480 id: Check@Home briefTitle: Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2027-11-01 date: 2028-11-01 date: 2024-03-26 date: 2024-03-26 name: Prof. Dr. Folkert W. Asselbergs class: OTHER name: Dutch Cardiovascular Alliance name: University Medical Center Groningen name: Dutch Heart Foundation name: Dutch Kidney Foundation name: Dutch Diabetes Research Foundation name: Maastricht University name: AstraZeneca BV name: UMC Utrecht name: Radboud University Medical Center name: Siemens Healthineers Nederland BV name: University of Twente name: Roche Diagnostics Nederland BV name: Luscii healthtech BV name: Happitech BV name: Stichting Radboud Universiteit name: Stichting Netherlands Heart Institute briefSummary: The aim of the Check@Home consortium is to set up a roadmap and infrastructure for a program to early detect atrial fibrillation and chronic kidney disease in the general population.
* Phase 2: Depending on the results on these home-based tests, subjects will be invited for further screening in a diagnostic screening facility. During this visit, physical data will be collected (height, weight, waist circumference, blood pressure, heart rhythm), blood will be drawn, and urine will be collected for the assessment of parameters that are indicative of a cardiovascular disease, chronic kidney disease, type 2 diabetes or their risk factors. Participants will receive a questionnaire that include questions on demographics, educational level, disease history, medication use, health literacy, and quality of life.
* Effectiveness of the albuminuria screening, compared with standard care, based on the incidence of kidney failure events and Major Adverse Cardiovascular Events (MACE). conditions: Atrial Fibrillation conditions: Chronic Kidney Diseases conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Check@Home is a population-based screening with a phased assessment and implementation using an iterative design executed consecutively in four regions in the Netherlands. primaryPurpose: SCREENING masking: NONE count: 320000 type: ESTIMATED name: Intervention group measure: Participation rate of the atrial fibrillation and albuminuria screening measure: Yield of the atrial fibrillation and albuminuria screening measure: Effectiveness of the atrial fibrillation screening measure: Effectiveness of the albuminuria screening measure: Effectiveness of the atrial fibrillation screening based on incidence of MACE events measure: Effectiveness of the albuminuria screening based on incidence each individual MACE component measure: Safety of the atrial fibrillation screening measure: Cost-effectiveness of screening strategies compared with standard of care: treatment effectiveness based on literature. measure: Cost-effectiveness of screening strategies compared to standard of care: treatment effectiveness based on actual observed event rates measure: False-positive rate, false-negative rate, sensitivity, specificity, positive predictive screening on atrial fibrillation and albuminuria screening. measure: Characteristics of responders and non-responders measure: Effectiveness of the atrial fibrillation screening based on incidence each individual MACE component measure: Overall effectiveness of broader population-based screening strategies applied to screening on heart failure, coronary artery disease, and type 2 diabetes. sex: ALL minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False